2-(3-hydroxypicolinamido)acetic acid

ID: ALA1256568

Chembl Id: CHEMBL1256568

Cas Number: 3458-69-3

PubChem CID: 9837038

Max Phase: Preclinical

Molecular Formula: C8H8N2O4

Molecular Weight: 196.16

Molecule Type: Small molecule

Names and Identifiers

Synonyms: 2-(3-Hydroxypicolinamido)Acetic Acid | HPCG|3458-69-3|2-[(3-hydroxypyridin-2-yl)formamido]acetic acid|2-(3-Hydroxypicolinamido)Acetic Acid|N-[(3-Hydroxypyridin-2-Yl)carbonyl]glycine|CHEMBL1256568|N-[(3-Hydroxy-2-pyridinyl)carbonyl]-glycine|MD6|4ie5|SCHEMBL704958|2-[(3-hydroxypyridine-2-carbonyl)amino]acetic Acid|IZQMRNMMPSNPJM-UHFFFAOYSA-N|3-hydroxypyridine-2-carbonylglycine|BDBM50328019|AKOS010147143|AS-16890|HY-119617|CS-0070060|EN300-115421|2-[(3-hydroxypyridin-2-yl)formamido]aceticacid|[(3-HShow More⌵

Canonical SMILES:  O=C(O)CNC(=O)c1ncccc1O

Standard InChI:  InChI=1S/C8H8N2O4/c11-5-2-1-3-9-7(5)8(14)10-4-6(12)13/h1-3,11H,4H2,(H,10,14)(H,12,13)

Standard InChI Key:  IZQMRNMMPSNPJM-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA1256568

   N-[(3-Hydroxypyridin-2-Yl)carbonyl]glycine

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 196.16

Molecular Weight (Monoisotopic): 196.0484

AlogP: -0.40

#Rotatable Bonds: 3

Polar Surface Area: 99.52

Molecular Species: ACID

HBA: 4

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 3

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 2.15

CX Basic pKa: 3.31

CX LogP: -0.58

CX LogD: -3.67

Aromatic Rings: 1

Heavy Atoms: 14

QED Weighted: 0.61

Np Likeness Score: -0.73

References

1. Conejo-Garcia A, McDonough MA, Loenarz C, McNeill LA, Hewitson KS, Ge W, Liénard BM, Schofield CJ, Clifton IJ..  (2010)  Structural basis for binding of cyclic 2-oxoglutarate analogues to factor-inhibiting hypoxia-inducible factor.,  20  (20): [PMID:20822901] [10.1016/j.bmcl.2010.08.032]

2. Woon EC, Demetriades M, Bagg EA, Aik W, Krylova SM, Ma JH, Chan M, Walport LJ, Wegman DW, Dack KN, McDonough MA, Krylov SN, Schofield CJ..  (2012)  Dynamic combinatorial mass spectrometry leads to inhibitors of a 2-oxoglutarate-dependent nucleic acid demethylase.,  55  (5): [PMID:22263962] [10.1021/jm201417e]

3. Aik W, Demetriades M, Hamdan MK, Bagg EA, Yeoh KK, Lejeune C, Zhang Z, McDonough MA, Schofield CJ..  (2013)  Structural basis for inhibition of the fat mass and obesity associated protein (FTO).,  56  (9): [PMID:23547775] [10.1021/jm400193d]

4. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]

5. Shishodia S, Demetriades M, Zhang D, Tam NY, Maheswaran P, Clunie-O'Connor C, Tumber A, Leung IKH, Ng YM, Leissing TM, El-Sagheer AH, Salah E, Brown T, Aik WS, McDonough MA, Schofield CJ..  (2021)  Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors.,  64  (22.0): [PMID:34762429] [10.1021/acs.jmedchem.1c01204]

6. Perry GS, Das M, Woon ECY..  (2021)  Inhibition of AlkB Nucleic Acid Demethylases: Promising New Epigenetic Targets.,  64  (23.0): [PMID:34792334] [10.1021/acs.jmedchem.1c01694]

Source

Source(2):

• Scientific Literature
• AstraZeneca Deposited Data